<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159159</url>
  </required_header>
  <id_info>
    <org_study_id>2003.325</org_study_id>
    <nct_id>NCT00159159</nct_id>
  </id_info>
  <brief_title>LOW CYCLO: Study Evaluating the Benefit of Two Doses of Ciclosporine in de Novo Cardiac Transplant</brief_title>
  <official_title>LOW CYCLO: A Multicenter, Prospective, Randomized Study Evaluating the Benefit, on Renal Function, of Two Doses of Ciclosporine: Low Dose Versus Usual Dose, in Association With Mycophenolate and Corticoïds, in de Novo Cardiac Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  Evaluation of the benefit on renal function of one year of a low dose of ciclosporine&#xD;
           versus the usual dose&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
        -  To evaluate the immunosuppressive efficacy and tolerance of the treatment&#xD;
&#xD;
      Study Duration:&#xD;
&#xD;
      Twelve months for each patient&#xD;
&#xD;
      Study Treatment: Ciclosporine&#xD;
&#xD;
      Group A: low dose &gt;= 130 µg/l &lt; T0 ciclosporinemia &lt; 200 µg/l; Group B: standard dose &gt;= 200&#xD;
      µg/l &lt; T0 ciclosporinemia &lt; 300 µg/l.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      One visit every 15 days, for the first three months; then 1 visit every month, for 6 months;&#xD;
      and 1 visit at 9 and 12 months.&#xD;
&#xD;
      Associated Treatments:&#xD;
&#xD;
        -  Mycophenolate (Cellcept®), 3g a day&#xD;
&#xD;
        -  Corticoids, as used for transplanted patients&#xD;
&#xD;
      Randomization: Randomization will occur when it is decided that ciclosporine will be&#xD;
      introduced.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2004</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of renal function, as assessed by the evolution between the two treatment groups at 12 months versus baseline serum creatinine level</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under curve of creatinine at 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin C level at 1, 2, 3, 6 and 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance at 6 and 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria and microalbuminuria at 6 and 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes include those linked to the immunosuppressive efficacy and tolerance of the treatment: Difference in appearance incidence of acute graft reject and adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial biopsy (International Society of Heart and Lung Transplantation [ISHLT] grades)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the evolution of left ventricular function and cardiovascular risk factors between the two groups at 6 and 12 months versus baseline: left ventricular ejection fraction and shortening fraction (echocardiogram)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systolic and diastolic blood pressure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glycemia, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides</measure>
  </secondary_outcome>
  <enrollment>106</enrollment>
  <condition>Cardiac Transplantion</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporine 130 µg/l &lt; T0 ciclosporinemia &lt; 200 µg/l</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporine 200 µg/l &lt; T0 ciclosporinemia &lt; 300 µg/l</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Recipient:&#xD;
&#xD;
          -  Males or females, ages &gt; 18 &lt; 65.&#xD;
&#xD;
          -  First cardiac transplant.&#xD;
&#xD;
          -  Negative pregnancy test for females of childbearing potential, at screening. Efficient&#xD;
             method of contraception must be used during the study.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Donor:&#xD;
&#xD;
          -  Cold ischemia duration &lt; 6 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Recipient:&#xD;
&#xD;
          -  Unstable hemodynamic status at randomization.&#xD;
&#xD;
          -  Patient with assisted circulation, considered unstable.&#xD;
&#xD;
          -  Serum creatinine &gt; 250 µmol/l.&#xD;
&#xD;
          -  Nursing or pregnant females.&#xD;
&#xD;
          -  HIV positive.&#xD;
&#xD;
          -  PCR hepatitis C virus (HCV) positive or hepatitis B surface (Hbs) antigen positive&#xD;
             (within 6 months prior to study).&#xD;
&#xD;
          -  Multi-organ graft or retransplant.&#xD;
&#xD;
          -  History of cancer (evolving, or within 5 years, except for epidermoid or basocellular&#xD;
             localised cutaneous carcinoma).&#xD;
&#xD;
          -  Use of any investigational product and/or participation in another clinical research&#xD;
             study within the last 30 days prior to study entry.&#xD;
&#xD;
          -  Any substance abuse or any psychiatric disorder&#xD;
&#xD;
          -  Contra-indication to study treatments.&#xD;
&#xD;
          -  Unable to introduce ciclosporine within 4 days after transplant.&#xD;
&#xD;
        Donor:&#xD;
&#xD;
          -  Known coronary pathology or cardiac disease.&#xD;
&#xD;
          -  HBsAg positive or HCV positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale BOISSONNAT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pascale BOISSONNAT</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>April 26, 2007</last_update_submitted>
  <last_update_submitted_qc>April 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2007</last_update_posted>
  <keyword>Cardiac Transplant</keyword>
  <keyword>ciclosporine</keyword>
  <keyword>immunosuppressive</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

